23andme, Inc.

Rinat Neuroscience Corporation

Pfizer Corporation

Davide Foletti

David L Shelton

Pavel Strop

Erik E Karrer

Germaine Fuh-Kelly

Yao-ming Huang

Lindsay Deis

Christine Wolak

Kristie Ibarra

Dominic Samuel Berns

Quan Zheng

Arvind Rajpal

Russell Dushin

Javier Fernando Chaparro Riggers

Wenwu Zhai

Magdalena Grazyna Dorywalska

Katherine Anne Delaria

Jacob Eli Gunn Glanville

Lee Mary Beth Shaughnessy

The present invention provides binding proteins, such as antibodies and antigen-binding fragments, which specifically bind to human interleukin-1 receptor accessory protein (hu-IL1RAP) and fully block the IL-1, IL-33, and IL-36 intracellular signaling pathways. Compositions comprising such binding proteins and methods of making and using such binding proteins are also provided.

Method of treating asthma with anti-IL1RAP antibodies

The present invention provides transglutaminase-mediated antibody-drug conjugates with high anti-body-drug ratio (DAR) comprising 1) glutamine-containing tags, endogenous glutamines, and/or endogenous glutamines made reactive by antibody engineering or an engineered transglutaminase (e.g., with altered substrate specifity); and 2) amine donor agents comprising amine donor units, linkers, and agent moieties, wherein the DAR is at least about 5. The invention also provides methods of making and methods of using such higher drug loaded antibody-drug conjugates.

Antibody-drug conjugates with high drug loading

Anti-IL1RAP antibodies

The present invention provides antagonizing antibodies that bind toalpha-toxin. The invention further provides a method of obtaining such antibodies and antibody encoding nucleic acids. The invention further relates to therapeutic methods for use of these antibodies for the treatment and/or prevention of staphylococcal disease, including, for example, pneumonia, bacteremia, sepsis, eye infection, and abscess.

[object Object]

Growing community of inventors

Menlo Park, CA, United States of America

Davide Foletti